3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
2
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Interventions
Specimen Handling
219
pembrolizumab
199
Magnetic Resonance Spectroscopy
197
Carboplatin
173
Cisplatin
139
Biopsy
133
Nivolumab
129
Paclitaxel
115
Radiotherapy
111
Cyclophosphamide
111
Gemcitabine
104
durvalumab
90
Dexamethasone
90
atezolizumab
76
Radiation
72
Rituximab
71
Lenalidomide
69
Pemetrexed
66
Doxorubicin
65
Bevacizumab
65
Docetaxel
62
Ipilimumab
58
Etoposide
57
olaparib
55
Fluorouracil
52
venetoclax
50
Taxes
50
Radiosurgery
50
Oxaliplatin
50
Prednisone
49
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
90 days
×
Clear all
NCT03049189
2026-04-06
COMPETE
ITM Solucin GmbH
Phase 3
Active not recruiting
324 enrolled
15 charts